nodes	percent_of_prediction	percent_of_DWPC	metapath
Tacrolimus—ORM1—saliva—attention deficit hyperactivity disorder	0.0949	0.121	CbGeAlD
Tacrolimus—PPP3CA—forebrain—attention deficit hyperactivity disorder	0.0435	0.0553	CbGeAlD
Tacrolimus—ABCA5—midbrain—attention deficit hyperactivity disorder	0.0425	0.054	CbGeAlD
Tacrolimus—PPP3CA—cardiovascular system—attention deficit hyperactivity disorder	0.0368	0.0467	CbGeAlD
Tacrolimus—ABCA5—nervous system—attention deficit hyperactivity disorder	0.035	0.0444	CbGeAlD
Tacrolimus—ABCA5—central nervous system—attention deficit hyperactivity disorder	0.0337	0.0428	CbGeAlD
Tacrolimus—ABCA5—cerebellum—attention deficit hyperactivity disorder	0.0329	0.0418	CbGeAlD
Tacrolimus—MTOR—forebrain—attention deficit hyperactivity disorder	0.0321	0.0408	CbGeAlD
Tacrolimus—FKBP1A—forebrain—attention deficit hyperactivity disorder	0.0289	0.0367	CbGeAlD
Tacrolimus—PPP3CA—midbrain—attention deficit hyperactivity disorder	0.0287	0.0365	CbGeAlD
Tacrolimus—MTOR—cardiovascular system—attention deficit hyperactivity disorder	0.0272	0.0345	CbGeAlD
Tacrolimus—ABCA5—brain—attention deficit hyperactivity disorder	0.0267	0.034	CbGeAlD
Tacrolimus—FKBP1A—cardiovascular system—attention deficit hyperactivity disorder	0.0244	0.0311	CbGeAlD
Tacrolimus—PPP3CA—nervous system—attention deficit hyperactivity disorder	0.0236	0.03	CbGeAlD
Tacrolimus—PPP3CA—central nervous system—attention deficit hyperactivity disorder	0.0227	0.0289	CbGeAlD
Tacrolimus—PPP3CA—cerebellum—attention deficit hyperactivity disorder	0.0222	0.0282	CbGeAlD
Tacrolimus—FKBP1A—Alpha-synuclein signaling—STUB1—attention deficit hyperactivity disorder	0.0218	0.103	CbGpPWpGaD
Tacrolimus—FKBP1A—TGF-beta receptor signaling activates SMADs—STUB1—attention deficit hyperactivity disorder	0.0213	0.1	CbGpPWpGaD
Tacrolimus—FKBP1A—midbrain—attention deficit hyperactivity disorder	0.0191	0.0243	CbGeAlD
Tacrolimus—PPP3CA—brain—attention deficit hyperactivity disorder	0.0181	0.0229	CbGeAlD
Tacrolimus—MTOR—nervous system—attention deficit hyperactivity disorder	0.0174	0.0222	CbGeAlD
Tacrolimus—MTOR—central nervous system—attention deficit hyperactivity disorder	0.0168	0.0213	CbGeAlD
Tacrolimus—MTOR—cerebellum—attention deficit hyperactivity disorder	0.0164	0.0209	CbGeAlD
Tacrolimus—FKBP1A—nervous system—attention deficit hyperactivity disorder	0.0157	0.0199	CbGeAlD
Tacrolimus—FKBP1A—central nervous system—attention deficit hyperactivity disorder	0.0151	0.0192	CbGeAlD
Tacrolimus—FKBP1A—cerebellum—attention deficit hyperactivity disorder	0.0148	0.0188	CbGeAlD
Tacrolimus—MTOR—brain—attention deficit hyperactivity disorder	0.0133	0.0169	CbGeAlD
Tacrolimus—ORM1—nervous system—attention deficit hyperactivity disorder	0.0123	0.0156	CbGeAlD
Tacrolimus—FKBP1A—brain—attention deficit hyperactivity disorder	0.012	0.0152	CbGeAlD
Tacrolimus—ORM1—central nervous system—attention deficit hyperactivity disorder	0.0118	0.015	CbGeAlD
Tacrolimus—FKBP1A—Loss of Function of SMAD2/3 in Cancer—STUB1—attention deficit hyperactivity disorder	0.0114	0.0535	CbGpPWpGaD
Tacrolimus—FKBP1A—Alpha-synuclein signaling—SLC6A3—attention deficit hyperactivity disorder	0.00923	0.0434	CbGpPWpGaD
Tacrolimus—ALB—brain—attention deficit hyperactivity disorder	0.00824	0.0105	CbGeAlD
Tacrolimus—PPP3CA—Spinal Cord Injury—RTN4—attention deficit hyperactivity disorder	0.00798	0.0375	CbGpPWpGaD
Tacrolimus—PPP3CA—Alzheimers Disease—CACNA1C—attention deficit hyperactivity disorder	0.00723	0.034	CbGpPWpGaD
Tacrolimus—ABCB1—forebrain—attention deficit hyperactivity disorder	0.00669	0.0085	CbGeAlD
Tacrolimus—FKBP1A—Spinal Cord Injury—RTN4—attention deficit hyperactivity disorder	0.00619	0.0291	CbGpPWpGaD
Tacrolimus—ABCB1—cardiovascular system—attention deficit hyperactivity disorder	0.00565	0.00718	CbGeAlD
Tacrolimus—CYP3A4—nervous system—attention deficit hyperactivity disorder	0.00513	0.00651	CbGeAlD
Tacrolimus—CYP3A4—central nervous system—attention deficit hyperactivity disorder	0.00494	0.00627	CbGeAlD
Tacrolimus—MTOR—FSH signaling pathway—BDNF—attention deficit hyperactivity disorder	0.00472	0.0222	CbGpPWpGaD
Tacrolimus—ABCB1—midbrain—attention deficit hyperactivity disorder	0.00442	0.00561	CbGeAlD
Tacrolimus—PPP3CA—Initiation of transcription and translation elongation at the HIV-1 LTR—EP300—attention deficit hyperactivity disorder	0.00423	0.0199	CbGpPWpGaD
Tacrolimus—MTOR—Insulin Signaling—SNAP23—attention deficit hyperactivity disorder	0.00401	0.0189	CbGpPWpGaD
Tacrolimus—ABCB1—nervous system—attention deficit hyperactivity disorder	0.00363	0.00461	CbGeAlD
Tacrolimus—ABCB1—central nervous system—attention deficit hyperactivity disorder	0.0035	0.00444	CbGeAlD
Tacrolimus—ABCB1—cerebellum—attention deficit hyperactivity disorder	0.00342	0.00434	CbGeAlD
Tacrolimus—FKBP1A—Calcium Regulation in the Cardiac Cell—CACNA1C—attention deficit hyperactivity disorder	0.00338	0.0159	CbGpPWpGaD
Tacrolimus—PPP3CA—Spinal Cord Injury—BDNF—attention deficit hyperactivity disorder	0.00333	0.0156	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by ERBB2—STUB1—attention deficit hyperactivity disorder	0.00326	0.0153	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—MB21D1—attention deficit hyperactivity disorder	0.00281	0.0132	CbGpPWpGaD
Tacrolimus—ABCB1—brain—attention deficit hyperactivity disorder	0.00277	0.00352	CbGeAlD
Tacrolimus—FKBP1A—Spinal Cord Injury—BDNF—attention deficit hyperactivity disorder	0.00258	0.0121	CbGpPWpGaD
Tacrolimus—PPP3CA—MAPK Signaling Pathway—BDNF—attention deficit hyperactivity disorder	0.00251	0.0118	CbGpPWpGaD
Tacrolimus—MTOR—HSF1-dependent transactivation—EP300—attention deficit hyperactivity disorder	0.00249	0.0117	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00222	0.0104	CbGpPWpGaD
Tacrolimus—FKBP1A—Role of Calcineurin-dependent NFAT signaling in lymphocytes—EP300—attention deficit hyperactivity disorder	0.00216	0.0101	CbGpPWpGaD
Tacrolimus—FKBP1A—TGF-beta Receptor Signaling—EP300—attention deficit hyperactivity disorder	0.00216	0.0101	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—POLR3A—attention deficit hyperactivity disorder	0.00206	0.00968	CbGpPWpGaD
Tacrolimus—PPP3CA—C-MYB transcription factor network—EP300—attention deficit hyperactivity disorder	0.00196	0.00919	CbGpPWpGaD
Tacrolimus—CYP3A4—Estrogen metabolism—COMT—attention deficit hyperactivity disorder	0.00181	0.0085	CbGpPWpGaD
Tacrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—BDNF—attention deficit hyperactivity disorder	0.00176	0.00825	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—RTN4—attention deficit hyperactivity disorder	0.00171	0.00806	CbGpPWpGaD
Tacrolimus—CYP3A7—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00165	0.00777	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—MB21D1—attention deficit hyperactivity disorder	0.00163	0.00768	CbGpPWpGaD
Tacrolimus—MTOR—Cellular response to heat stress—EP300—attention deficit hyperactivity disorder	0.00161	0.00756	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—STUB1—attention deficit hyperactivity disorder	0.00158	0.00744	CbGpPWpGaD
Tacrolimus—MTOR—Insulin Signaling—SNAP25—attention deficit hyperactivity disorder	0.00157	0.00737	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00149	0.00699	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—STUB1—attention deficit hyperactivity disorder	0.00146	0.00687	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00146	0.00685	CbGpPWpGaD
Tacrolimus—MTOR—IFN-gamma pathway—EP300—attention deficit hyperactivity disorder	0.00146	0.00685	CbGpPWpGaD
Tacrolimus—ALB—SLC-mediated transmembrane transport—SLC9A9—attention deficit hyperactivity disorder	0.00134	0.00629	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00131	0.00616	CbGpPWpGaD
Tacrolimus—MTOR—BDNF signaling pathway—BDNF—attention deficit hyperactivity disorder	0.00124	0.00582	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—MB21D1—attention deficit hyperactivity disorder	0.00122	0.00575	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—POLR3A—attention deficit hyperactivity disorder	0.0012	0.00564	CbGpPWpGaD
Tacrolimus—CYP3A5—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.0012	0.00562	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—STUB1—attention deficit hyperactivity disorder	0.00114	0.00535	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—STUB1—attention deficit hyperactivity disorder	0.00113	0.00532	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—ADRA2C—attention deficit hyperactivity disorder	0.00108	0.00507	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.00102	0.00481	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00102	0.00478	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.00101	0.00475	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—POLR3A—attention deficit hyperactivity disorder	0.000898	0.00422	CbGpPWpGaD
Tacrolimus—CYP3A7—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000885	0.00416	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.000883	0.00415	CbGpPWpGaD
Tacrolimus—PPP3CA—RNF mutants show enhanced WNT signaling and proliferation—EP300—attention deficit hyperactivity disorder	0.000883	0.00415	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000879	0.00413	CbGpPWpGaD
Tacrolimus—CYP3A7—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000879	0.00413	CbGpPWpGaD
Tacrolimus—CYP3A7—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000873	0.0041	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000861	0.00405	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000845	0.00397	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000821	0.00386	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by WNT in cancer—EP300—attention deficit hyperactivity disorder	0.00082	0.00385	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000795	0.00374	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000793	0.00373	CbGpPWpGaD
Tacrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.000786	0.00369	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000782	0.00367	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000772	0.00363	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000719	0.00338	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—MB21D1—attention deficit hyperactivity disorder	0.000713	0.00335	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—SNAP25—attention deficit hyperactivity disorder	0.000693	0.00326	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—STUB1—attention deficit hyperactivity disorder	0.00069	0.00324	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000682	0.0032	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.00068	0.00319	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by Wnt—EP300—attention deficit hyperactivity disorder	0.000676	0.00318	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000668	0.00314	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000655	0.00308	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.000648	0.00305	CbGpPWpGaD
Tacrolimus—CYP3A5—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00064	0.00301	CbGpPWpGaD
Tacrolimus—MTOR—Disease—STUB1—attention deficit hyperactivity disorder	0.000637	0.00299	CbGpPWpGaD
Tacrolimus—CYP3A5—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000635	0.00298	CbGpPWpGaD
Tacrolimus—CYP3A5—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000631	0.00296	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000597	0.00281	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.000596	0.0028	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.000572	0.00269	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.000568	0.00267	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—ADRA2A—attention deficit hyperactivity disorder	0.000566	0.00266	CbGpPWpGaD
Tacrolimus—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.000556	0.00261	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—ADRA2C—attention deficit hyperactivity disorder	0.000556	0.00261	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—SNAP25—attention deficit hyperactivity disorder	0.000537	0.00252	CbGpPWpGaD
Tacrolimus—MTOR—Integrated Breast Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.000534	0.00251	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—POLR3A—attention deficit hyperactivity disorder	0.000523	0.00246	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000522	0.00245	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000504	0.00237	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000485	0.00228	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.00047	0.00221	CbGpPWpGaD
Tacrolimus—ALB—SLC-mediated transmembrane transport—SLC6A3—attention deficit hyperactivity disorder	0.000465	0.00219	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000463	0.00218	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000462	0.00217	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000456	0.00214	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000446	0.0021	CbGpPWpGaD
Tacrolimus—ABCB1—HIF-1-alpha transcription factor network—EP300—attention deficit hyperactivity disorder	0.000445	0.00209	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—attention deficit hyperactivity disorder	0.000425	0.002	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000425	0.002	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—EP300—attention deficit hyperactivity disorder	0.000419	0.00197	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000405	0.0019	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000383	0.0018	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000376	0.00177	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000376	0.00176	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000368	0.00173	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000364	0.00171	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000362	0.0017	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000358	0.00168	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000354	0.00166	CbGpPWpGaD
Tacrolimus—MTOR—Cellular responses to stress—EP300—attention deficit hyperactivity disorder	0.000341	0.0016	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000329	0.00155	CbGpPWpGaD
Tacrolimus—MTOR—Disease—SNAP25—attention deficit hyperactivity disorder	0.000302	0.00142	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000298	0.0014	CbGpPWpGaD
Tacrolimus—CYP3A4—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000297	0.0014	CbGpPWpGaD
Tacrolimus—CYP3A4—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000295	0.00139	CbGpPWpGaD
Tacrolimus—CYP3A4—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000293	0.00138	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—ADRA2A—attention deficit hyperactivity disorder	0.000292	0.00137	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000262	0.00123	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.00026	0.00122	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—TPH2—attention deficit hyperactivity disorder	0.00025	0.00117	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.00025	0.00117	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000246	0.00115	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—EP300—attention deficit hyperactivity disorder	0.000244	0.00115	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.000237	0.00111	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000231	0.00108	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000228	0.00107	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000228	0.00107	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000225	0.00106	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—EP300—attention deficit hyperactivity disorder	0.000225	0.00106	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000212	0.000994	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.000207	0.000974	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000205	0.000963	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000201	0.000946	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.0002	0.000938	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000199	0.000935	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000197	0.000927	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.00019	0.000894	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.00019	0.000893	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000185	0.000871	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—EP300—attention deficit hyperactivity disorder	0.000183	0.000858	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000181	0.000848	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000181	0.000848	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000178	0.000835	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—EP300—attention deficit hyperactivity disorder	0.000175	0.00082	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000165	0.000776	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000158	0.000741	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000155	0.000731	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000155	0.000731	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000153	0.000719	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—COMT—attention deficit hyperactivity disorder	0.000151	0.000711	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—MAOA—attention deficit hyperactivity disorder	0.00015	0.000706	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000144	0.000678	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000142	0.000668	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000137	0.000646	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000136	0.00064	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000136	0.00064	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000134	0.00063	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.00013	0.00061	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000125	0.000586	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000124	0.000584	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000122	0.000574	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000122	0.000571	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000118	0.000556	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—COMT—attention deficit hyperactivity disorder	0.000109	0.000514	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000109	0.000512	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000109	0.00051	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—EP300—attention deficit hyperactivity disorder	0.000106	0.0005	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000104	0.000487	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—EP300—attention deficit hyperactivity disorder	9.96e-05	0.000468	CbGpPWpGaD
Tacrolimus—MTOR—Disease—EP300—attention deficit hyperactivity disorder	9.82e-05	0.000461	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—COMT—attention deficit hyperactivity disorder	9.42e-05	0.000443	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—MAOA—attention deficit hyperactivity disorder	9.35e-05	0.00044	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	9.07e-05	0.000426	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—TPH2—attention deficit hyperactivity disorder	8.39e-05	0.000394	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CACNB2—attention deficit hyperactivity disorder	8.39e-05	0.000394	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—DPYD—attention deficit hyperactivity disorder	8.26e-05	0.000388	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—COMT—attention deficit hyperactivity disorder	8.25e-05	0.000388	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—MAOA—attention deficit hyperactivity disorder	8.2e-05	0.000385	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CACNA1C—attention deficit hyperactivity disorder	7.68e-05	0.000361	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—EP300—attention deficit hyperactivity disorder	6.87e-05	0.000323	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—SNAP25—attention deficit hyperactivity disorder	6.71e-05	0.000315	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—EP300—attention deficit hyperactivity disorder	6.49e-05	0.000305	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ADRA2A—attention deficit hyperactivity disorder	6.39e-05	0.0003	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—COMT—attention deficit hyperactivity disorder	5.08e-05	0.000239	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—MAOA—attention deficit hyperactivity disorder	5.05e-05	0.000237	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—EP300—attention deficit hyperactivity disorder	4.69e-05	0.00022	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—EP300—attention deficit hyperactivity disorder	4.04e-05	0.00019	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—EP300—attention deficit hyperactivity disorder	3.54e-05	0.000166	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—EP300—attention deficit hyperactivity disorder	2.18e-05	0.000102	CbGpPWpGaD
